Investigating the effects of a medication for obesity on heart and metabolic health in young people with type 1 diabetes
Obesity complicating type 1 diabetes in young people: Physiology and Impact of GLP-1 analogue anti-obesity treatment on cardiometabolic risk factors
This study is looking at how a special medication can help young people with type 1 diabetes manage their weight and improve their health, by checking things like body fat and how their bodies use insulin.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10898805 on NIH RePORTER |
What this research studies
This research focuses on understanding how a GLP-1 analogue medication can help manage obesity and its related health risks in young individuals with type 1 diabetes. The study will assess various physiological factors, including fat distribution and insulin resistance, using advanced imaging techniques and metabolic tests. By examining these factors, the research aims to determine how effective this treatment is in reducing cardiometabolic risks associated with obesity in this population. Participants will undergo several assessments, including MRI scans and metabolic testing, to gather comprehensive data on their health.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and young adults diagnosed with type 1 diabetes who are also experiencing obesity.
Not a fit: Patients without type 1 diabetes or those who are not struggling with obesity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for young people with type 1 diabetes and obesity, potentially reducing their risk of cardiovascular diseases.
How similar studies have performed: Previous research has shown promising results with GLP-1 analogue treatments in managing obesity and metabolic health, indicating potential for success in this study.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Van Name, Michelle — Yale University
- Study coordinator: Van Name, Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.